Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12048762 | 0.92 | TLR7 (0.71) | TLR7 | |
| SCHEMBL5530824 | 0.91 | TLR7 (0.60) | TLR7 | |
| Fumaric Acid SCHEMBL5528753 | 0.90 | TLR7 (0.56) | TLR7 | |
| Fumaric Acid SCHEMBL5528766 | 0.90 | TLR7 (0.56) | TLR7 | |
| SCHEMBL2387843 | 0.89 | TLR7 (0.63) | TLR7 | |
| SCHEMBL12049066 | 0.88 | TLR7 (0.73) | TLR7 | |
| SCHEMBL4126391 | 0.88 | TLR7 (0.60) | TLR7 | |
| SCHEMBL5524578 | 0.86 | TLR7 (0.61) | TLR7 | |
| SCHEMBL4130549 | 0.86 | TLR7 (0.60) | TLR7 | |
| SCHEMBL9971018 | 0.85 | TLR7 (0.73) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-8969362-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-02-13 | — | — | US | disclosed |
| US-8575180-B2 | 9-substituted 8-oxoadenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2013-11-05 | — | — | US | disclosed |
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | ASTRAZENECA AKTIEBOLAG (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1728793-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306610-A1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | IFNAR1, IL5, IFNG | TLR7 8/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | TLR7 8/4885 |
| US-20140045837-A1 | 9-Substituted 8-Oxoadenine Compound | IFNAR1, IL5, IFNG | TLR7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.